CSS
ALXO icon

Cubist Systematic Strategies’s ALX Oncology ALXO Stock Holding History

Cubist Systematic Strategies’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$14.7K Buy
+8,025
New +$6.95K ﹤0.01% 2913
2025
Q1 		– Sell
-32,021
Closed -$53.5K – 2817
2024
Q4 		$53.5K Sell
32,021
-351,491
-92% -$540K ﹤0.01% 2781
2024
Q3 		$698K Buy
383,512
+184,071
+92% +$684K ﹤0.01% 2040
2024
Q2 		$1.2M Buy
+199,441
New +$2.45M 0.01% 1635
2024
Q1 		– Sell
-65,814
Closed -$980K – 3666
2023
Q4 		$980K Buy
+65,814
New +$624K 0.01% 2077
2023
Q2 		– Sell
-33,869
Closed -$153K – 3444
2023
Q1 		$153K Sell
33,869
-2,472
-7% -$18.7K ﹤0.01% 3331
2022
Q4 		$410K Sell
36,341
-8,413
-19% -$94.5K ﹤0.01% 3150
2022
Q3 		$428K Sell
44,754
-42,585
-49% -$496K ﹤0.01% 3287
2022
Q2 		$707K Buy
87,339
+36,645
+72% +$399K ﹤0.01% 2765
2022
Q1 		$857K Sell
50,694
-9,801
-16% -$167K 0.01% 2156
2021
Q4 		$1.3M Buy
+60,495
New +$2.61M 0.01% 1713

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Cubist Systematic Strategies's ALXO Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in ALX Oncology (ALXO) in Q3 2025: 8,025 shares worth $14.7K. The stake represents ﹤0.01% of the portfolio and ranks #2913 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in ALXO as recently as Q4 2024.

Cubist Systematic Strategies first reported a position in ALXO in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.3M in Q4 2021. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

  • Cubist Systematic Strategies held 8,025 shares of ALX Oncology worth $14.7K as of Q3 2025.
  • ALX Oncology was a new Cubist Systematic Strategies position in Q3 2025.
  • ALX Oncology made up ﹤0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #2913 holding.
  • Cubist Systematic Strategies first reported a position in ALX Oncology in Q4 2021 and has held it in 11 quarters since.
  • Cubist Systematic Strategies's ALX Oncology position peaked at $1.3M in Q4 2021.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.